

N THE UNITED STATES PATENT AND TRADEMARK OF

1626

Applicant:

Title:

LABELED PEPTIDES, PROTEINS AND ANTIBODIES AND PROCESSES AND

INTERMEDIATES USEFUL FOR THEIR PREPARATION

Docket No.: Filed:

1361.007US1

Examiner:

April 20, 2001 Robert Shiao Serial No.: 09/839,577 Due Date: N/A

Group Art Unit: 1626

MS ISSUE FEE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

X A return postcard.

 \overline{X} An Amendment Under 37 C.F.R. 1.312 And Interview Summary (8 Pages).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: Robin A. Chadwick

Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS ISSUE FEE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this / day of October, 2094;

CANDIS BUENDING

Name

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

<u>S/N 09/839577</u> <u>PATENT</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Klaus M. Hahn et al.

Examiner: Robert Shiao

Serial No.:

09/839577

Group Art Unit: 1626

Filed:

April 20, 2001

Docket No.: 1361.007US1

Title:

LABELED PEPTIDES, PROTEINS AND ANTIBODIES AND PROCESSES

AND INTERMEDIATES USEFUL FOR THEIR PREPARATION

AMENDMENT UNDER 37 CFR § 1.312 AND INTERVIEW SUMMARY

MS ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

This Amendment under 37 C.F.R. § 1.312 is provided in response to the Examiner's Amendment provided with the Notice of Allowance mailed on September 8, 2004. Please amend the above-identified patent application as follows.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 7 of this paper.